MedTrace Logo

Neurologic Morbidity and Disability in Acute Lymphoblastic Leukemia Survivors

NCT00664131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2011-09-23

No results posted yet for this study

Summary

Treatment of acute lymphoblastic leukemia achieves high cure rate, but is potentially neurotoxic.

Long-term neurologic morbidity in survivors and its effect on function are inadequately studied.

Neurologic outcomes will be assessed through an investigator administered questionnaire followed by comprehensive neurologic examination by the study neurologist.

Conditions

Interventions

OTHER

Neurological Examination/Questionnaires

See Detailed Description section for description of treatment plan.

Sponsors & Collaborators

Principal Investigators

  • Kirsten Ness, PT, PhD · St. Jude Children's Research Hospital

Eligibility

Min Age
6 Years
Max Age
28 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664131 on ClinicalTrials.gov